Author details

Full Name

Helmut Butzkueven

Affiliation

ORCID

Career Start Year

1997

Papers

314

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37584176	The Patient-Determined Disease Steps scale is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis.		2024
36846149	Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies.		2023
36171104	Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.	Journal of Neurology, Neurosurgery and Psychiatry	2023
35894247	Prediction of relapse activity when switching to cladribine for multiple sclerosis.	Multiple Sclerosis Journal	2023
35761144	An Update on the Measurement of Motor Cerebellar Dysfunction in Multiple Sclerosis.	Cerebellum	2023
36149605	Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.		2023
36433775	Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.	Multiple Sclerosis Journal	2023
36448302	Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity.	Brain	2023
37852514	A comprehensive review of the advances in neuromyelitis optica spectrum disorder.		2023
37675878	The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis.		2023
37739566	A genetic basis for the severity of multiple sclerosis.		2023
38085684	Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.		2023
38085047	Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.		2023
37709946	Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.		2023
37628757	DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes.	Int J Mol Sci	2023
37972580	Plug-and-play microphones for recording speech and voice with smart devices.		2023
38061621	Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review.		2023
37414538	Risk of secondary progressive multiple sclerosis after early worsening of disability.		2023
37414534	Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.		2023
37287269	A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.		2023
37273217	Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.		2023
36765422	Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis.		2023
36816812	Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.		2023
37392018	Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis.		2023
37325639	Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis.		2023
36876595	Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis.		2023
36753921	Peripheral monocytes and soluble biomarkers in autoimmune encephalitis.		2023
37068931	Disability accrual in primary and secondary progressive multiple sclerosis.		2023
37001409	Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review.		2023
36800908	Comparative effectiveness in multiple sclerosis: A methodological comparison.		2023
36746088	Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.		2023
36692895	Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.		2023
37437240	Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.		2023
37369086	The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.		2023
37307006	Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.		2023
36931078	Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.	Mult Scler Relat Disord	2023
37230311	The impact of menopause on multiple sclerosis.		2023
37352902	Conceiving complexity: Biological mechanisms underpinning the lasting effect of pregnancy on multiple sclerosis outcomes.		2023
36851894	Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.		2023
37541839	Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.		2023
35101840	Electroclinical biomarkers of autoimmune encephalitis.	Epilepsy and Behavior	2022
35595048	Rare antibody-mediated and seronegative autoimmune encephalitis: An update.	Autoimmunity Reviews	2022
35460305	Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis Consortium.	European Journal of Neurology	2022
36105273	Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool.	Multiple Sclerosis Journal - Experimental, Translational and Clinical	2022
35840036	Psychiatric manifestations of autoimmune encephalitis.	Autoimmunity Reviews	2022
35519901	Comprehensive clinical, radiological, pathological and biochemical analysis required to differentiate VV1 sporadic Creutzfeldt-Jakob disease from suspected variant CJD.	BMJ Neurology Open	2022
35582938	Confirmed disability progression as a marker of permanent disability in multiple sclerosis.	European Journal of Neurology	2022
36158958	Early predictors of visual and axonal outcomes after acute optic neuritis.	Front Neurol	2022
35637426	Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.	BMC Medical Research Methodology	2022
35373638	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.	Mult Scler	2022